Sale!

Keytruda ( Pembrolizumab ) 100mg/4ml

$1,600.28

20 in stock

Category: COSMETICS AND BEAUTY MACHINES

Description
Reviews (0)

BUY KEYTRUDA ONLINE

Buy keytruda online a cancer drug also called pembrolizumab (Inj Keytruda from Merck) prevents the growth and metastasis of cancer cells in the body. Advanced skin cancer (melanoma) that has migrated to other parts of the body or cannot be surgically removed is treated with Keytruda. If your tumor carries a certain genetic marker that your doctor will test for, it is also used to treat a specific type of non-small cell lung cancer. Additionally, it is used to treat head and neck cancer that has returned after previous therapy or spread to other body regions.

How is Keytruda (pembrolizumab) taken?

The standard dosage :

Melanoma: 200 mg every 3 weeks
NSCLC: 200 mg every 3 weeks
HNSCC: 200 mg every 3 weeks
cHL: 200 mg every 3 weeks for adults and 2 mg/kg (up to 200mg) every 3 weeks for pediatrics
Urothelial Carcinoma: 200 mg every 3 weeks
MSI-H Cancer: 200 mg every 3 weeks for adults and 2 mg/kg (up to 200 mg) every 3 weeks for children
Gastric Cancer: 200 mg every 3 weeks.

Administer as an intravenous infusion over 30 minutes.

For children with cHL and MSI-H, how much Keytruda (pembrolizumab) is needed depends on the body weight.

Complete information about Keytruda (pembrolizumab) dose and administration can be found in the official prescribing information listed in our references section^[1,2,3].

Note: Please consult with your treating doctor for personalised dosing

This medication has a restricted distribution and is ordinarily not offered by pharmacies.

Only a few specialist pharmacies carry this medication, which typically means:

It might be pricey.

This cannot be found at a typical pharmacy.

Manage the complicated regimen for this medication.

An insurance provider, the government, or a non-profit organization may cover the cost of this medication for patients who require it. The manufacturer may also provide support if you lack insurance or need aid with your co-pay.

- It may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “nonsquamous” and your tumor does not have an abnormal “EGFR” or “ALK” gene.
- It may be used with the chemotherapy medicines carboplatin and either paclitaxel or paclitaxel protein-bound as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “squamous.”
- It may be used alone as your first treatment when your lung cancer has not spread outside your chest (stage III) and you cannot have surgery or chemotherapy with radiation, or your NSCLC has spread to other areas of your body (advanced NSCLC), and your tumor tests positive for “PD-L1” and does not have an abnormal “EGFR” or “ALK” gene.
- It may also be used alone for advanced NSCLC if you have tried chemotherapy that contains platinum and it did not work or is no longer working and, your tumor tests positive for “PD-L1” and if your tumor has an abnormal “EGFR” or “ALK” gene, you have also received an “EGFR” or “ALK” inhibitor medicine that did not work or is no longer working.
a kind of cancer called head and neck squamous cell cancer (HNSCC).
- It may be used with the chemotherapy medicines fluorouracil and a platinum as your first treatment when your head and neck cancer has spread or returned and cannot be removed by surgery.
- It may be used alone as your first treatment when your head and neck cancer has spread or returned and cannot be removed by surgery, and your tumor tests positive for “PD-L1.”
- It may be used alone when your head and neck cancer has spread or returned, andyou have received chemotherapy that contains platinum and it did not work or is no longer working.
a kind of cancer called classical Hodgkin lymphoma (cHL). It may be used
- in adults when:
- - your cHL has returned or
  - you have tried a treatment and it did not work, or
- in children when:
- - you have tried a treatment and it did not work, or
  - your cHL has returned after you received 2 or more types of treatment.
a kind of cancer called primary mediastinal B-cell lymphoma (PMBCL). It may be used in adults and children when you have tried a treatment and it did not work, or your PMBCL has returned after you received 2 or more types of treatment.
a kind of bladder and urinary tract cancer called urothelial carcinoma.
- It may be used when your cancer has not spread to nearby tissue in the bladder, but is at high-risk for spreading (high-risk, non-muscle invasive bladder cancer [NMIBC])and when your tumor is a type called “carcinoma in situ” (CIS), and you have tried treatment with Bacillus Calmette-Guerin (BCG) and it did not work, and you are not able to or have decided not to have surgery to remove your bladder.
- It may be used when your bladder or urinary tract cancer has spread or cannot be removed by surgery (advanced urothelial cancer), and you are not able to receive chemotherapy that contains platinum (medicines called either cisplatin or carboplatin).
- It may be used when your bladder or urinary tract cancer has spread or cannot be removed by surgery (advanced urothelial cancer), and you have received chemotherapy that contains platinum, and it did not work or is no longer working.
a kind of cancer that is shown by a laboratory test to be a microsatellite instability-high (MSI-H) or a mismatch repair deficient (dMMR) solid tumor. It may be used in adults and children to treat:
- cancer that has spread or cannot be removed by surgery (advanced cancer), and
- has progressed following treatment, and you have no satisfactory treatment options.
This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
It is not known if KEYTRUDA is safe and effective in children with MSI-H cancers of the brain or spinal cord (central nervous system cancers).
a kind of cancer called colon or rectal cancer. It may be used when your cancer:
- has spread or cannot be removed by surgery (advanced colon or rectal cancer), and
- has been shown by a laboratory test to be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
a kind of stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- It may be used in combination with the medicine trastuzumab along with fluoropyrimidine and platinum chemotherapy as your first treatment when your stomach cancer:
- - is HER2-positive, and
  - has spread or cannot be removed by surgery (advanced gastric cancer).
This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
a kind of cancer called esophageal or certain gastroesophageal junction (GEJ) carcinomas that cannot be cured by surgery or a combination of chemotherapy and radiation therapy.
- It may be used with platinum- and fluoropyrimidine-based chemotherapy medicines.
- It may be used alone when:
- - you have received one or more types of treatment, and it did not work or it is no longer working, and
  - your tumor is a type called “squamous,” and
  - your tumor tests positive for “PD-L1.”
a kind of cancer called cervical cancer that tests positive for “PD-L1.”
- It may be used with chemotherapy medicines, with or without the medicine bevacizumab, when your cervical cancer does not go away (persistent), has returned, or has spread (advanced cervical cancer).
- It may be used alone when your cervical cancer:
- - has returned, or has spread or cannot be removed by surgery (advanced cervical cancer), and
  - you have received chemotherapy, and it did not work or is no longer working.
a kind of liver cancer called hepatocellular carcinoma. It may be used after you have received the medicine sorafenib.
This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
a kind of skin cancer called Merkel cell carcinoma (MCC) in adults and children. It may be used when your cancer has spread or returned.
This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
a kind of kidney cancer called renal cell carcinoma (RCC).
- It may be used with the medicine axitinib as your first treatment when your kidney cancer has spread or cannot be removed by surgery (advanced RCC).
- It may be used alone if you are at intermediate-high or high risk of your kidney cancer (RCC) coming back after surgery to:
- - remove all or part of your kidney, or
  - remove all or part of your kidney and also surgery to remove cancer that has spread to other parts of the body (metastatic lesions).
a kind of uterine cancer called endometrial carcinoma. It may be used alone:
- if your cancer is shown by a laboratory test to be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and
- you have received anti-cancer treatment, and it is no longer working, and
- your cancer cannot be cured by surgery or radiation (advanced endometrial carcinoma).
a kind of skin cancer called cutaneous squamous cell carcinoma (cSCC). It may be used when your skin cancer has returned or spread, and cannot be cured by surgery or radiation.
a kind of cancer called triple-negative breast cancer (TNBC).
- It may be used with chemotherapy medicines as treatment before surgery and then continued alone after surgery when you have early-stage breast cancer, and are at high risk of your breast cancer coming back (high-risk early-stage triple-negative breast cancer [TNBC]).
- It may be used with chemotherapy medicines when your breast cancer has returned and cannot be removed by surgery or has spread (advanced TNBC), and tests positive for “PD-L1.”

PD-L1 = programmed death ligand 1;
EGFR = epidermal growth factor receptor;
ALK = anaplastic lymphoma kinase;
HER2 = human epidermal growth factor receptor 2.

Important Safety Information

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen any time during treatment or even after your treatment has ended.

Call or see your health care provider right away if you develop any signs or symptoms of the following problems or if they get worse. These are not all of the signs and symptoms of immune system problems that can happen with KEYTRUDA:

Lung problems: cough, shortness of breath, or chest pain.

Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

Liver problems: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); dark urine (tea colored); or bleeding or bruising more easily than normal.

Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness.

Kidney problems: decrease in the amount of your urine; blood in your urine; swelling of your ankles; loss of appetite.

Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in your mouth or in your nose, throat, or genital area; fever or flu-like symptoms; swollen lymph nodes.

Problems can also happen in other organs and tissues. Signs and symptoms of these problems may include: chest pain; irregular heartbeat; shortness of breath; swelling of ankles; confusion; sleepiness; memory problems; changes in mood or behavior; stiff neck; balance problems; tingling or numbness of the arms or legs; double vision; blurry vision; sensitivity to light; eye pain; changes in eyesight; persistent or severe muscle pain or weakness; muscle cramps; low red blood cells; bruising.
we also have Keytudra 25mg and 50mg available at our warehouse

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feeling like passing out, fever, and back pain.

Rejection of a transplanted organ. Your health care provider should tell you what signs and symptoms you should report and they will monitor you, depending on the type of organ transplant that you have had.

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with KEYTRUDA. Your health care provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your health care provider will check you for these problems during treatment with KEYTRUDA. They may treat you with corticosteroid or hormone replacement medicines. They may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Before you receive KEYTRUDA, tell your health care provider if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant or have had or plan to have a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic); have had radiation treatment in your chest area; have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome.

If you are pregnant or plan to become pregnant, tell your health care provider. KEYTRUDA can harm your unborn baby. If you are able to become pregnant, you will be given a pregnancy test before you start treatment. Use effective birth control during treatment and for at least 4 months after your final dose of KEYTRUDA. Tell them right away if you think you may be pregnant or you become pregnant during treatment with KEYTRUDA.

Tell your health care provider if you are breastfeeding or plan to breastfeed. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your final dose of KEYTRUDA.

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Common side effects of KEYTRUDA when used alone include feeling tired; pain, including pain in muscles; rash; diarrhea; fever; cough; decreased appetite; itching; shortness of breath; constipation; bones or joints and stomach-area (abdominal) pain; nausea; and low levels of thyroid hormone.

In children, when KEYTRUDA is used alone, fever, vomiting, upper respiratory tract infection, headache, and low levels of white blood cells and red blood cells (anemia) are more common than in adults.

Common side effects of KEYTRUDA when given with certain chemotherapy medicines include feeling tired or weak; nausea; constipation; diarrhea; decreased appetite; rash; vomiting; cough; trouble breathing; fever; hair loss; inflammation of the nerves that may cause pain, weakness, and paralysis in the arms and legs; swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina; mouth sores; headache; weight loss; stomach-area (abdominal) pain; joint and muscle pain; and trouble sleeping.

Common side effects of KEYTRUDA when given with chemotherapy and bevacizumab include tingling or numbness of the arms or legs; hair loss; low red blood cell count; feeling tired or weak; nausea; low white blood cell count; diarrhea; high blood pressure; decreased platelet count; constipation; joint aches; vomiting; urinary tract infection; rash; low levels of thyroid hormone; and decreased appetite.

Common side effects of KEYTRUDA when given with axitinib include diarrhea; feeling tired or weak; high blood pressure; liver problems; low levels of thyroid hormone; decreased appetite; blisters or rash on the palms of your hands and soles of your feet; nausea; mouth sores or swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina; hoarseness; rash; cough; and constipation.

These are not all the possible side effects of KEYTRUDA. Talk to your health care provider for medical advice about side effects.